Jump to main content
Jump to site search


Photosensitizer Loaded Hemoglobin-Polymer Conjugate as a Nanocarrier for Enhanced Photodynamic Therapy

Abstract

Photodynamic therapy (PDT) has emerged as a promising therapeutic option for various cancers. During the photosensitizer mediated PDT procedure, oxygen is activated as reactive oxygen species (ROS) upon light irradiation to induce vascular damage and cancer cell death directly. However, the PDT efficiency can be seriously reduced in the hypoxic environment of tumour. Even worse, the oxygen consumption of PDT aggarevates the hypoxia, which leads to further inefficiency of PDT and other negative consequences. Herein, a new kind of hemoglobin-polymer conjugate (HbTcMs) was prepared as the carrier for both oxygen and the photosensitizer to enhance photodynamic therapy. The conjugated Hb exhibited an improved tolerance to the oxidation and trypsin digestion while retained the O2 binding capacity compared with free Hb. The HbTcMs conjugate showed little toxicity in darkness and could be effectively internalized by 4T1 cells. More importantly, the HbTcMs conjugate could highly produce the singlet oxygen (1O2) and kill the 4T1 cells in vitro under irradiation, exerting better phototoxicity than that without oxygen supply. Therefore, it is expected that the HbTcMs conjugate can be a potential oxygen carrier applied in photodynamic therapy.

Back to tab navigation

Supplementary files

Publication details

The article was received on 30 Nov 2017, accepted on 31 Jan 2018 and first published on 31 Jan 2018


Article type: Paper
DOI: 10.1039/C7TB03109B
Citation: J. Mater. Chem. B, 2018, Accepted Manuscript
  •   Request permissions

    Photosensitizer Loaded Hemoglobin-Polymer Conjugate as a Nanocarrier for Enhanced Photodynamic Therapy

    X. Xu, Y. Cui, H. Bu, J. Chen, Y. Li, G. Tang and L. Wang, J. Mater. Chem. B, 2018, Accepted Manuscript , DOI: 10.1039/C7TB03109B

Search articles by author

Spotlight

Advertisements